Four hundred and sixty-seven hematopoietic stem cell transplantations (HSCTs) (217 autologous and 250 allogeneic HSCT) were performed in 374 children at four pediatric HSCT centers in Korea from January 2005 to December 2007. Among 467 transplants, veno-occlusive disease (VOD) developed in 72 transplants (15.4%) at a median of 10 days after HSCT. Multivariate analysis showed that BU or TBI-containing regimen (P ¼ 0.002), VOD prophylaxis without lipo-prostaglandin E1 (PGE1) (P ¼ 0.012), number of previous HSCT (P ¼ 0.014), and pretransplant serum ferritin (P ¼ 0.018) were independent risk factors for developing VOD. Mean serum ferritin levels were significantly higher in HSCT with VOD (2109.6 ± 2842.5 ng/ml) than in HSCT without VOD (1315.9±1094.4 ng/ml) (Po0.001). The relative risk of death within 100 days of HSCT in transplants with VOD compared with transplants without VOD was 3.39 (confidence interval: 1.78-6.45). Our results suggest that lipo-PGE1 might have a protective effect against the development of VOD, and pretransplant serum ferritin could act as a risk factor for VOD. A larger prospective study is needed to confirm a possible role of lipo-PGE1 and iron chelation therapy in reducing the incidence of VOD.
Introduction
Hepatic veno-occlusive disease (VOD) is a frequent and often fatal complication of hematopoietic stem cell transplantation (HSCT). The incidence of VOD in the pediatric transplant population is in the range of 11-31%, with an associated death rate of up to 50%. [1] [2] [3] [4] Known risk factors for VOD are pre-existing liver disease, 5, 6 second myeloablative HSCT or allogeneic HSCT beyond the second relapse, 7, 8 history of gemtuzumab ozogamicin treatment, 9 BU/CY and/or melphalan-containing regimen, 10, 11 and pediatric diseases such as osteopetrosis and hemophagocytic lymphohistiocytosis. 12 Because of the limited treatment options available for VOD, prevention of fatal VOD is an obvious priority. Although drugs such as heparin, prostaglandin E1 (PGE1), ursodeoxycholic acid, pentoxiphylline, and low molecular weight heparin have been tested clinically for preventing VOD, their efficacy is either unconfirmed or preliminary. [13] [14] [15] [16] [17] [18] [19] Although defibrotide shows encouraging responses with little toxicity, a larger prospective randomized study is needed to confirm its efficacy in the prophylaxis setting. [20] [21] [22] In addition, the availability of defibrotide is limited to clinical studies and compassionate use. Therefore, a better understanding of the pathogenesis and risk factors of VOD is important to decrease VOD incidence.
Here, we report recent VOD characteristics in children with heterogeneous underlying diseases and HSCT from various stem cell donors. We evaluated the incidence, severity, risk factors, treatment, and clinical outcome in patients who underwent HSCT at four pediatric HSCT centers in Korea.
Patients and methods

Patients
From January 2005 to December 2007, 467 HSCT were performed in 374 children at Asan Medical Center, National Cancer Center, Samsung Medical Center, and Seoul National University Children's Hospital in Korea. Patient charts were reviewed for descriptive and laboratory data to identify possible risk factors for the development of VOD and for 100-day post transplant survival. The study was approved by the Institutional Review Board of Seoul National University Children's Hospital.
Diagnosis and classification of VOD
The diagnosis of VOD was based on the modified Seattle criteria, which require at least two of the following three events within 20 days of transplantation: bilirubin level 42 mg per 100 ml, hepatomegaly or right upper quadrant pain of liver origin, and 42% weight gain secondary to fluid accumulation. No other explanation for these symptoms and signs could be present at the time of diagnosis of VOD. VOD was also diagnosed in patients who showed these symptoms and signs after 20 days of HSCT with no other explanation. The severity of VOD was defined according to McDonald et al.:
23 mild for clinically manifested VOD that resolved without intervention; moderate for VOD that required treatment but resolved completely; and severe for VOD that caused persistent symptoms after day 100 or death before day 100 with ongoing VOD.
Prophylactic regimen for VOD VOD prophylactic regimen differed among the treatment centers (Table 1 ). In the first center, a combination of heparin and lipid microspheres-containing PGE1 (lipo-PGE1, alprostadil, Eglandin inj.; Welfide Korea Co, Ltd, Seoul, Korea) was the primary VOD prophylaxis regimen (n ¼ 108). In the second (n ¼ 18) and third centers (n ¼ 68), lipo-PGE1 was used for VOD prophylaxis. In the first and the second centers, defibrotide was also given to patients who were considered high risk for the development of VOD (n ¼ 35). In the last center, heparin was used primarily as a VOD prophylaxis (n ¼ 116); however, lipo-PGE1 was added if patients received TBI or underwent second or third transplantation (n ¼ 122). Heparin was administered at a dose of 100 IU/kg/day i.v. continuous infusion 12-24 h before the start of the conditioning regimen. Lipo-PGE1 was given at a dose of 1 mg/kg/day through continuous infusion, 12-24 h before the start of conditioning regimen. Therapy with heparin and/or lipo-PGE1 was continued until day 30 or until the day of discharge.
Risk factors
We analyzed factors potentially related to the development of VOD in three categories: (1) pretransplant factors: age, sex, diagnosis, number of transplants, interval between diagnosis and transplantation, total serum bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum ferritin, hepatitis serology, and baseline body weight; (2) transplant procedural factors: conditioning regimen, donor type, VOD prophylaxis regimen; (3) clinical course factors: development of GVHD, maximum body weight within day 30, maximum value of total serum bilirubin, pulmonary and renal function data, development of VOD, treatment of VOD, and duration of VOD. Pretransplantation AST and ALT were measured just before the beginning of the conditioning regimen. Pretransplantation serum ferritin was defined as the ferritin Table 1 Demographic and transplant data of the patients
Characteristics Number
Patients n ¼ 374 level within 30 days of the start of the conditioning regimen, when patients were not in a febrile episode. All diagnoses were divided into three groups: nonmalignant diseases (severe aplastic anemia, immune deficiency syndrome, metabolic diseases, or hemophagocytic lymphohistiocytosis), malignant diseases (ALL in first or second CR, AML in first CR, CML in chronic phase, high-risk brain tumors, or stage 4 neuroblastoma), and advanced malignant diseases (ALL in more than second CR, AML in greater than first CR, CML in greater than chronic phase, relapsed solid tumors or induction failure). BU was administered as a 2-h i.v. infusion every 6 h over 4 days. BU dose was defined according to body weight as follows: 1.1 mg/kg/dose for patients with body weight o12 kg, and 0.8 mg/kg/dose for patients with body weight X12 kg. In high-risk brain tumors and neuroblastoma, tandem highdose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was planned. In other high-risk or relapsed solid tumors, tandem or single HDCT/ASCR was performed according to institutional treatment strategies. When graft failure or relapse occurred after HSCT, second or third transplantation was performed if the patient's clinical condition allowed further transplantation. VOD-related multiorgan failure was defined as either an oxygen requirement with an oxygen saturation of 90% or less on room air or ventilation dependence; and/or renal dysfunction (define as a doubling of baseline creatinine and/or dialysis dependence); and/or encephalopathy after liver failure. The duration of VOD was defined to be the interval between the clinical diagnosis and complete resolution of symptoms with reduction of bilirubin by at least 50% or death.
Statistical analysis
Statistical analysis included Fisher's exact test, w 2 -test, or t-test when testing associations of independent variables. Variables with Po0.1 in univariate analysis were entered in the logistic regression model for multivariate analysis. Analysis of survival and toxic mortality was performed using the Kaplan-Meier method and log-rank test. All data analyses were performed using the SPSS statistical program (Version 12.0 for Windows, SPSS, Inc., Chicago, IL, USA). Table 1 shows the clinical characteristics of patients and their transplantations. One hundred and six transplantations were performed as the second HSCT, which comprised 86 planned tandem HSCT for high-risk or relapsed solid tumors, 12 transplants for graft failure of prior HSCT, and 8 transplants for relapse after the first HSCT. Third HSCTs were performed in nine patients: one for graft failure after the second HSCT and eight for relapse after the second HSCT. Five transplants (one second HSCT and four third HSCTs) were performed with reduced intensity conditioning regimen. The median duration of VOD prophylaxis was 28 days (range: 10-71). In 320 transplants using lipo-PGE1 alone or in-combination for VOD prophylaxis, early discontinuation occurred in five transplants, in which both heparin and lipo-PGE1 were used. Bleeding, such as hematochezia or hematemesis, was the cause of early discontinuation of heparin and lipo-PGE1 in three of five transplants, and fever in one transplant. In remaining one transplant, although the patient did not satisfy the diagnostic criteria of VOD, clinical findings progressed toward VOD. When the symptoms and signs reached a stage right before fulfilling diagnostic criteria of VOD, defibrotide was given with early discontinuation of lipo-PGE1 from day 20 of HSCT for treatment of VOD.
Results
Study patients
Incidence and characteristic of VOD VOD was diagnosed in 72 of 467 transplants (15.4%) at a median of 10 days (range: 1-64) after HSCT. VOD was graded as mild in 13, moderate in 49, and severe in 10. In nine transplants, VOD developed after 20 days of transplantation, occurred at day 21 in four transplants, day 30 in three transplants, day 31 in one transplant, and day 64 in one transplant. Severe VOD occurred in 6 of 63 VOD developed within 20 days of HSCT (9.5%) and in 4 of 9 VOD developed after 20 days of HSCT (44.4%) (P ¼ 0.018). The median onset of mild or moderate VOD was day 9 (range: 1-30) of HSCT and in severe VOD, day 16 (range: 2-64) (P ¼ 0.024). The median durations were 12 days (range: 3-80) for all VOD, 11 days (range: 3-40) in mild or moderate VOD, and 46 days (range: 13-80) in severe VOD. Table 2 shows the clinical characteristics of VOD. Hepatomegaly was the most common sign (87.5%) of VOD. Ascites, pulmonary dysfunction, and renal dysfunction were more common in HSCT with severe VOD compared with HSCT with mild or moderate VOD. There was no difference between the two groups in terms of maximum weight gain or serum total bilirubin after transplantation.
Risk factors for developing VOD
Significant factors in univariate analysis were age, allogeneic HSCT, BU or TBI-based conditioning regimen, elevated ALT before HSCT, and serum ferritin before HSCT X2000 ng/ml. The risk of VOD appeared to be different according to the age of patients: 21.1% in patients aged below 2 years, 11.6% in patients aged 2-10 years, and 20.7% in patients above 10 years (P ¼ 0.026). Allogeneic transplants appeared to have a higher risk of VOD compared with autologous transplants (21.2% vs 8.8%, Po0.001). BU or TBI in the conditioning regimen was associated with an increased risk of VOD (22.1 vs 8.1%, Po0.001). Elevated serum ALT (elevated ALT vs normal ALT, 21.8 vs 13.3%, P ¼ 0.027) or ferritin (ferritin X2000 ng/ml vs o2000 ng/ml, 22.9 vs 13.7%, P ¼ 0.014) before HSCT were also associated with increased risk of VOD. There was no difference in duration from diagnosis to transplantation between HSCT with VOD (16.4 ± 19.1 months) and without VOD (16.9 ± 20.3 months) (P ¼ 0.82). Chronic hepatitis B did not appear to increase the risk of VOD. Although three patients were hepatitis B carriers, none were afflicted with VOD. Previous CMV, EBV, HCV, or HSV infection, reflected with serology analysis, did not suggest increased risk of VOD. There was no patient who received hepatic irradiation before HSCT. The role of gemtuzumab ozogamicin was uncertain, as only one patient with AML received gemtuzumab ozogamicin before HSCT and had not developed VOD. In multivariate analysis, factors significantly associated with VOD were BU or TBI-based conditioning regimen, VOD prophylaxis without lipo-PGE1, number of HSCT, and pretransplantation serum ferritin (Table 3) . Mean serum ferritin levels were significantly higher in HSCT with VOD (2109.6± 2842.5 ng/ml) than in HSCT without VOD (1315.9 ± 1094.4 ng/ml) (Po0.001). However, there was no difference in serum ferritin level between HSCT with mild or moderate VOD (2080.2 ± 2989.7 ng/ml) and HSCT with severe VOD (2292.6 ± 1773.5 ng/ml) (P ¼ 0.323). The number of HSCT was the only significant risk factor for developing severe VOD (P ¼ 0.034). To study the relationship between serum ferritin and ALT, linear regressions between these two variables were analyzed. There was a significant correlation between ferritin and ALT (Pearson correlation coefficient: 0.307, Po0.001); however, prediction was poor (r 2 ¼ 0.094).
Outcome
After the diagnosis of VOD, patients with moderate/severe VOD had fluid and sodium restriction associated with one or more of the following measures: lipo-PGE1 (n ¼ 31), diuretics (n ¼ 23), tissue plasminogen activator (n ¼ 12), and defibrotide (n ¼ 7). Twenty-five (5.4%) treatmentrelated mortalities occurred within 100 days of transplantation. The causes of death were infection in 13, VOD-related multiorgan failure in 5, GVHD in 2, and others in 5. VODrelated mortality represented 1.1% of all transplants, 6.9% of cases of VOD, and 50% of cases of severe VOD. The cumulative incidence of treatment-related mortalities at day 100 of HSCT was higher in HSCT with VOD (15.3%) than HSCT without VOD (3.5%) (Po0.001). The relative risk of death within 100 days of HSCT in transplants with VOD compared with transplants without VOD was 3.39 (confidence interval: 1.78-6.45).
Discussion
The incidence of VOD in 3-year series of pediatric patients (January 2005 to December 2007) from four centers in Korea was 72/476 (15.4%). The literature for pediatric transplantation shows VOD incidence ranging from 11 to 31%, 1-4 which could be influenced by the variable incidence of risk factors, patient selection, and the definition of VOD. Furthermore, most of these studies looked at defined patient populations with respect to either the type of disease transplanted for and/or conditioning chemotherapeutic agents used. However, the design of our study, with its broader patient parameters and large pediatric population, provides general information on VOD regardless of diagnosis, type of transplantation, or specific chemotherapeutic agent.
Several studies described VOD developing 420 days after HSCT. Hasegawa et al. 6 suggested that late-onset VOD was caused by treatment for complications of HSCT, such as GVHD and infection, after liver injury after the conditioning regimen. In addition, Brugieres et al. 24 reported that the time of VOD onset appeared to determine two patterns of outcome: mild forms with early onset (before day 11) and more severe forms with late onset (after day 17), which was also shown in our results. However, Bearman et al. 25 suggested that the speed of bilirubin increase and weight gain was faster in severe VOD than in mild or moderate VOD, although they did not compare the Table 3 Multivariate analysis of risk factors for the development of VOD
Variables
Odds ratio (95% CI) P-value median day of VOD diagnosis. In this study, previous HSCT history, which was the only independent risk factor of severe VOD, was more frequent in late-onset VOD (6/9, 66.7%) than in VOD developed before day 20 of HSCT (17/63, 27.0%) (P ¼ 0.026). More frequent complications in second or third HSCT and prolonged treatment for complications might cause late and severe VOD. In addition, Toh et al. 26 suggested that effective VOD prophylaxis might result in a delayed onset of VOD. In this study, 9 out of 43 transplants given lipo-PGE1 for VOD prophylaxis were lateonset VOD, whereas there was no late-onset VOD in 29 transplants not given lipo-PGE1 (P ¼ 0.009).
The type and intensity of conditioning regimen can influence the incidence of VOD. VOD risk increases with TBI dose, radiation dose rate, and dose of BU. [27] [28] [29] BU or TBI-containing regimens were independent risk factors for developing VOD in this study. In several studies, a lower incidence of VOD among patients receiving low or fractionated doses of TBI, as opposed to those who received single or higher doses of TBI. 28, 29 The proposed mechanism by which BU may increase the risk of VOD is through glutathione depletion at high doses. A greater area under the time to serum concentration curve after medication dosage was significantly correlated with an increased risk of developing VOD. 30 The modulation of the total dose of BU by determining the area under the curve is possible option to overcome this undesired negative effect of BU. Recently, the adoption of reduced intensity conditioning regimens and the use of drugs with less hepatic toxicity such as treosulphan and fludarabine, have been associated with a lower incidence of VOD. 31, 32 PGE1 is a potent vasodilator with inhibitory effects on platelet aggregation, anti-inflammatory, and prothrombolytic activity. When considering pathophysiology of VOD, PGE1 may have a part in decreasing VOD, but clinical results were variable. Gluckman et al. 18 reported that the use of prophylactic PGE1 through continuous intravenous infusion decreased the overall incidence of VOD. Song et al. 19 reported the possible beneficial effect of lipo-PGE1 to prevent development of VOD. However, Bearman et al. 33 reported that PGE1 caused significant toxicities, such as cutaneous erythema, desquamation, fluid retention, and hypotension with no convincing evidence of benefit. One possible reason for these differences is that PGE1 is rapidly metabolized in the lungs. 34 To circumvent this problem of PGE1, inactivation after its intravenous administration, lipo-PGE1 was developed, and several studies found that effects of lipo-PGE1 are more potent than those of free PGE1 with fewer side effects. 35, 36 Benefits of lipid microspheres preparations are attributed to avoidance of the inactivation of drugs, as well as a favorable uptake by reticuloendothelial systems, including inflammatory cells. 36, 37 Mizushima et al. 38 demonstrated that radiolabeled lipo-PGE1 accumulated more densely in the vascular wall than did free PGE1, especially in vascular lesions. This indicates that lipo-PGE1 penetrates vascular endothelium and then accumulates in blood vessels to result in augmentation of the pharmacological action of prostaglandin. These findings suggest the usefulness of lipid microspheres as a carrier of prostaglandin to vascular lesions. In this study, lipo-PGE1 showed protective effect against the development of VOD. Larger prospective trials are warranted to confirm this effect.
Iron catalyzes the formation of hydroxyl radicals, which are powerful prooxidants that attack cellular membrane lipid, proteins, and nucleic acids, and hepatic iron accumulation causes liver inflammation and fibrosis. Furthermore, high-dose chemotherapy rapidly depletes intracellular antioxidants and represents a significant oxidative challenge to the liver. 39 Ferritin is clearly not an ideal measure for total body iron burden. However, the measurement of liver iron concentration with liver biopsy is an invasive procedure, especially in patients undergoing HSCT. We used pretransplantation serum ferritin as a surrogate marker of iron burden at the time of transplantation, based on the low cost and easy measurement, its correlation with directly measured liver iron content in several studies, 40 and its established clinical relevance in other settings. 41 In this study, pretransplantation serum ferritin was an independent risk factor of developing VOD, and elevated ferritin caused elevated ALT before transplant, reflecting liver inflammation. Morado et al. 42 analyzed the risk factors in 22 out of 180 adult patients, who developed VOD, and found a correlation with pretransplant ferritin levels. In a study by Armand et al., 43 pretransplantation ferritin was associated with a borderline significant increase in the risk of VOD (P ¼ 0.054) in 590 adult patients who underwent allogeneic HSCT. In a study of pediatric patients, Jastaniah et al. 44 showed that VOD developed in 5 of 15 patients, and VOD was associated with liver inflammation and elevated liver iron concentration. In this study, pretransplantation ferritin was a significant risk factor for developing VOD, and it might be associated with iron overload and hepatic injury induced by oxygen radicals resulting from iron-mediated catalysis.
The limitation of the present retrospective review includes the differences in record keeping across physicians and institutions, and possible selection biases. However, we included relevant data from patients who had undergone HSCT in four centers to minimize selection biases. Another limitation of this study is the lack of patient randomization to each VOD prophylactic regimen; therefore, further studies are needed to confirm our findings.
In conclusion, VOD is not an uncommon complication of pediatric HSCT and causes significant mortality. This study showed that pretransplantation serum ferritin increased the risk of VOD, in addition to well-known risk factors of developing VOD, such as BU or TBI-containing regimen and previous history of transplantation. Our study also justified the role of lipo-PGE1 in prophylaxis of VOD; however, prospective randomized controlled study is needed to confirm this. Defibrotide is not widely available, despite promising results for VOD treatment and prophylaxis. Reducing the incidence of VOD by reducing its risk factors will improve transplantation outcomes. Our results confirm many of the previously described risk factors for VOD. More importantly, this study have an implication that pretransplantation serum ferritin could act as a risk factor in pediatric patients undergoing HSCT. A larger prospective study is needed to confirm a possible role of iron chelation therapy in reducing the incidence of VOD.
